Gilead Sciences CEO Sells Millions in Shares Amid Executive Stock Disposals

According to a U.S. Securities and Exchange Commission filing, Gilead Sciences, Inc. (GILD) CEO Daniel O’Day sold roughly 15,000 shares of the company’s stock in the open market on June 1, generating about $1.98 million in proceeds. After the transaction, his direct holdings decreased to 617,567 shares. Earlier, on May 15, Chief Commercial and External Affairs Officer Johanna Mercier exercised stock options to acquire shares and then sold a portion, raising approximately $3.5–3.6 million (mid-4 billion KRW). That same day, CFO Andrew D. Dickinson sold 3,000 shares for about $396,810 (around 500 million KRW). All three transactions were executed under pre-established Rule 10b5-1 trading plans, with Mercier’s option exercise structured on a cash-less basis tied to market sales.

Recently, Gilead has heightened expectations of securing the long-acting oral HIV-prevention market after the U.S. Food and Drug Administration accepted the New Drug Application for Yeztugo, a once-weekly oral candidate. In 2026, the company has also taken proactive business and financial steps to bolster its T-cell engager pipeline for autoimmune diseases, including the acquisition of Ouro Medicines and the issuance of $3 billion in unsecured senior notes. ()

Gilead is a U.S. biopharmaceutical leader with core strengths in HIV, hepatitis, antivirals, and oncology. It is best known for the COVID-19 treatment remdesivir and its comprehensive HIV treatment and prevention portfolio. Since 2019, Daniel O’Day has served as both CEO and Board Chair, overseeing major acquisitions and the expansion of oncology and immunology pipelines.